May 16 (Reuters) - British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon. (Reporting by Anchal Rana in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,766 GBX | +2.11% | -0.45% | +21.81% |
May. 31 | US FDA approves Moderna's RSV vaccine, its second marketed product | RE |
May. 30 | Goldman Sachs Starts GSK With Neutral Rating, $47 Price Target | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,766 GBX | +2.11% | -0.45% | 89.9B | ||
325.1 GBX | +0.12% | +0.65% | 37.79B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.81% | 89.9B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK intends to sell its entire stake in Haleon